Navigation Links
Brain Cancer Vaccine's Immune Response Key to Outcomes
Date:7/15/2008

Tumor-altering shot, already in trials, lengthens survival, study finds

TUESDAY, July 15 (HealthDay News) -- An in-trial dendritic cell vaccine that fights malignant brain tumors called glioblastoma multiforme (GBM) may help boost a patient's immunity response and improve the outcome, a new report says.

An article in the July 15 issue of Cancer Research says this would mark the first time a tumor-altering therapeutic intervention would have shown such promise.

"Fifty-three percent of patients in our study exhibited a significant vaccine-enhanced immune response. Compared to non-responders or those with limited responses, the vaccine responders had significantly longer times to tumor progression and longer survival," one the article's authors, Cedars-Sinai's Department of Neurosurgery Chairman Dr. Keith L. Black, said in a news release issued by the Los Angeles-based medical center.

The study also supports past findings that the dendritic cell vaccination can work well with chemotherapy to improve treatment. The researchers reported that the time to tumor progression greatly increased when chemotherapy followed vaccination, compared to vaccination alone.

"No other vaccine trial in cancer patients has shown the kind of progressive correlation between immune responses and clinical outcomes that we found," the article's first and corresponding author, Christopher J. Wheeler, a research scientist at the Maxine Dunitz Neurosurgical Institute, said in the same news release.

These results, centered on 32 patients enrolled in a Phase II clinical trial, included 17 patients having significant positive response after three vaccinations, while 15 showed no such responsiveness. Average time to tumor progression (based on when tumor volume increased by about 25 percent on MRI scans) was 308 days among responders, compared to 167 days for non-responders.

The average length of survival was about 21 months among responders, about 14 months for non-responders. Forty-one percent of vaccine responders survived at least two years, though, compared with only 7 percent of non-responders.

All those in the trial showed a longer time to progression and longer time of survival, on average, than patients undergoing standard treatment without vaccination.

More information

The Brain Tumor Society has more about brain cancer.



-- Kevin McKeever



SOURCE: Cedars-Sinai Medical Center, news release, July 15, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Draining away brains toxic protein to stop Alzheimers
2. Vision restoration therapy shown to improve brain activity in brain injured patients
3. Clinical depression linked to abnormal emotional brain circuits
4. Brain imaging reveals breakdown of normal emotional processing
5. Brain cells work differently than previously thought
6. Vaccine Stops Alzheimers Brain Tangles
7. Research may unlock mystery of autisms origin in the brain
8. Scientists Spot Brains Free Will Center
9. Free will takes flight: how our brains respond to an approaching menace
10. Alcoholics With Cirrhosis Have More Brain Damage
11. Brain Lesions Predict MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... Usually, the impending arrival of warmer weather means the gleeful ... a double chin, this means more anxiety than elation. The cosmetic dermatology experts at ... a double chin is undesirable,” Dr. Goldman said, “but it seems doubly so when ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Radiology Business Management Association (RBMA) ... as its new executive director. Mr. Still was selected through a careful months-long search ... as he is known to our members, has been a part of building the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, and the ... results and maintaining GMP and USP compliance. In a new webinar from METTLER ... requirements " these requirements are explained. The challenge is to determine how ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... physicians, Paul Yost, will begin serving as new board chair for Orange County ... Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, which ...
(Date:3/28/2017)... ... March 28, 2017 , ... Qualidigm , ... corporate headquarters to a new, more expansive office space in order to accommodate ... purchased a distressed office building in Wethersfield, Conn. located at 936 Silas Deane ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... -- The global surgical sealants and ... USD 4.5 billion by 2025, according to a new ... injured tissues post operation is a major step to ... 3% to 15% of cases and are considered as ... of postoperative deaths in patients. Surgical sealants and adhesives ...
(Date:3/28/2017)... , March 28, 2017 ... to reach USD 8.0 billion by 2025, according to ... increasing incidence of infectious diseases and cancer is expected ... in disease diagnosis over the coming years. In addition, ... of autologous and allogenic stem cell therapy, due to ...
(Date:3/28/2017)... Taiwan , March 28, 2017  Medeon ... medical device company, is pleased to announce that ... A investment of Panther Orthopedics, Inc., a ... innovative dynamic fixation solutions for orthopedic extremity applications.  ... continues to expand rapidly, primarily due to procedure ...
Breaking Medicine Technology: